RSCM
MYGN icon

Rail-Splitter Capital Management’s Myriad Genetics MYGN Stock Holding History

Rail-Splitter Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-111,108
Closed -$3.93M – 43
2015
Q1 		$3.93M Buy
+111,108
New +$3.98M 1.2% 36

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rail-Splitter Capital Management's MYGN Position: Q2 2015 in Review

Rail-Splitter Capital Management sold out of Myriad Genetics (MYGN) in Q2 2015, closing a stake of 111,108 shares — an estimated $3.93M sold.

Rail-Splitter Capital Management first reported a position in MYGN in Q1 2015 and held it in 1 quarter. The position peaked at $3.93M in Q1 2015. 234 funds tracked by Wall St. Rank hold MYGN as of Q2 2015.

  • Rail-Splitter Capital Management reported no remaining Myriad Genetics position as of Q2 2015 after selling out during the quarter.
  • Rail-Splitter Capital Management sold 111,108 Myriad Genetics shares in Q2 2015, an estimated $3.93M.
  • Rail-Splitter Capital Management first reported a position in Myriad Genetics in Q1 2015 and held it in 1 quarter.
  • Rail-Splitter Capital Management's Myriad Genetics position peaked at $3.93M in Q1 2015.
  • 234 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2015.

Based on Rail-Splitter Capital Management's 13F filing for Q2 2015, filed 31 Jul 2015.